Biogen Reports First Quarter 2017 Revenues of $2.8 Billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
Biogen (BIIB) PT Raised to $280 at Stifel
April 25, 2017 11:18 AM EDTStifel analyst Thomas Shrader raised his price target on Biogen (NASDAQ: BIIB) to $280.00 (from $265.00) while maintaining a Hold rating following results this morning.
The analyst noted the results were positive for the companys goal to trim some of the fat from... More
Biogen (BIIB) Tops Q1 EPS by 20c
April 25, 2017 7:00 AM EDTBiogen (NASDAQ: BIIB) reported Q1 EPS of $5.20, $0.20 better than the analyst estimate of $5.00. Revenue for the quarter came in at $2.8 billion versus the consensus estimate of $2.74 billion.
Total revenues of $2.8 billion, a 3% increase versus the prior year and an 8% increase excluding hemophilia... More


